Keytruda set to become cornerstone of kidney cancer treatment

4 September 2019

Nearly a year after Merck & Co (NYSE: MRK) presented strong data for its Keytruda (pembrolizumab) combo in renal cell carcinoma (RCC), the firm has won approval in Europe.

Together with Pfizer’s (NYSE: PFE) Inlyta (axitinib), a tyrosine kinase inhibitor, the therapy met both primary endpoints of overall survival (OS) and progression-free survival (PFS) in the KEYNOTE-426 trial.

The combination reduced the risk of death by 47% compared with Sutent (sunitinib), and is widely expected to become a new standard of care in this indication.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK